|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.49 USD | +0.21% |
|
-.--% | +1.76% |
| 05-05 | BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says | MT |
| 04-28 | Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Global BMI Index | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 4.55B | - | - | - | - | - |
| 46.06B | |||||
| 38.91B | - | - | - | - | - |
| 35.57B | |||||
| 33.13B | |||||
| 26.42B |
Select your edition
All financial news and data tailored to specific country editions
